Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The U.S. may be headed for a “choose your own adventure” approach to vaccine policy, in which skeptical parents follow the ...

After years of updates on COVID-19 vaccines and boosters, it can be confusing to know who should get a shot and when. While a lot of that confusion has to do with the new COVID strains that ...

The newly reconstituted CDC Advisory Committee on Immunization Practices will meet this week. Packed with antivaxxers, the ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from ...

In adults 60 and over, vaccine effectiveness from October 2023 to March 2024 against RSV-associated hospitalization reached 75% (95% CI 50-87), according to researchers led by Diya Surie ...

A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

Published in the Journal of the American Medical Association (JAMA), the letter says that the dismissal of the advisors and ...